BriaCell Therapeutics annual current ratio
2020
2021
2022
2023
2024
2025
BriaCell Therapeutics Current Ratio Growth & History (BCTX)
BriaCell Therapeutics's current ratio was 5.01 for fiscal 2025.
View full BriaCell Therapeutics company overviewBriaCell Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-07-31 | 5.01 | 4.52 | +922.88% |
| 2024 | 2024-07-31 | 0.49 | −14.47 | −96.73% |
| 2023 | 2023-07-31 | 14.96 | −30.04 | −66.76% |
| 2022 | 2022-07-31 | 45.00 | −58.81 | −56.65% |
| 2021 | 2021-07-31 | 103.81 | 103.74 | +157269.77% |
| 2020 | 2020-07-31 | 0.07 | — | — |
BriaCell Therapeutics quarterly current ratio
Q4.20
Q4.21
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-04-30 | 7.07 | 3.66 | +107.15% |
| Q2 2026 | 2026-01-31 | 10.10 | 8.73 | +637.72% |
| Q1 2026 | 2025-10-31 | 3.42 | 1.77 | +107.61% |
| Q4 2025 | 2025-07-31 | 5.01 | 4.52 | +922.88% |
| Q3 2025 | 2025-04-30 | 3.41 | 2.60 | +317.21% |
| Q2 2025 · Jan 31 | 2025-01-31 | 1.37 | −1.62 | −54.24% |
| Q1 2025 | 2024-10-31 | 1.65 | −15.94 | −90.63% |
| Q4 2024 | 2024-07-31 | 0.49 | −14.47 | −96.73% |
| Q3 2024 | 2024-04-30 | 0.82 | −20.51 | −96.16% |
| Q2 2024 | 2024-01-31 | 2.99 | −47.63 | −94.09% |
| Q1 2024 | 2023-10-31 | 17.59 | −21.65 | −55.18% |
| Q4 2023 | 2023-07-31 | 14.96 | −30.04 | −66.76% |
| Q3 2023 | 2023-04-30 | 21.33 | −104.87 | −83.10% |
| Q2 2023 | 2023-01-31 | 50.62 | −29.22 | −36.59% |
| Q1 2023 | 2022-10-31 | 39.24 | — | — |
| Q4 2022 | 2022-07-31 | 45.00 | −58.81 | −56.65% |
| Q3 2022 | 2022-04-30 | 126.20 | — | — |
| Q2 2022 | 2022-01-31 | 79.84 | — | — |
| Q4 2021 | 2021-07-31 | 103.81 | 103.74 | +157269.77% |
| Q4 2020 | 2020-07-31 | 0.07 | — | — |
BriaCell Therapeutics current ratio trends
Over the last five fiscal years, BriaCell Therapeutics's current ratio increased from 0.07 to 5.01, a change of 4.94. The latest reported quarter, Q3 2026, shows 7.07.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BriaCell Therapeutics source filings ↗